Patient Groups Rank ViiV Top Of Pharma Reputation League Table, Again
This article was originally published in Scrip
Executive Summary
The latest PatientView report on the corporate reputation of pharma from the perspective of patient groups has been published. In a survey of pharma's corporate reputation, ViiV Healthcare retained the overall top spot, with AbbVie a close second. Of the 48 companies that patient groups commented on, the bottom ranked companies were Valeant and Hospira.
You may also be interested in...
Big Pharma's Bad Attitude: Are CEOs Giving Industry A Bad Rep?
Big pharma has been big news recently, with politicians and the general public wading into industry debates on drug pricing, profit-making and trial transparency under the gleeful eye of the international press. Unsurprisingly, pharma has come out on the losing side of these debates, its scientific accomplishments forced into the shadows by the actions of executives such as Martin Shkreli, who have ensured that the spotlight is firmly on the people behind the businesses rather than the products they manufacture.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.